<DOC>
	<DOCNO>NCT01464112</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability establish maximum tolerated dose JNJ-26481585 combine VELCADE dexamethasone .</brief_summary>
	<brief_title>A Dose Escalation Study Histone Deacetylase Inhibitor ( HDACi ) JNJ 26481585 Combination With VELCADE ( Bortezomib ) Dexamethasone Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>This open-label ( patient study personnel know treatment administer ) , multicenter , dose escalation study . Increasing dose JNJ-26481585 explored combination standard VELCADE/dexamethasone dose . After maximum tolerate dose ( MTD ) determine , 24 patient enter treatment group receive MTD ( deem necessary low dose level ) ass safety activity combination . There 3 phase study : Screening Phase ( sign inform consent immediately dose ) , open-label Treatment Phase ( first dose JNJ-26481585 VELCADE-dexamethasone End Treatment Visit ) , Posttreatment/Follow-up Phase . Patients achieve positive response treatment end Cycle 1 continue receive JNJ-26481585 VELCADE-dexamethasone maximum 11 cycle ( eight 3-week treatment cycle , follow three 5-week treatment cycle ) . Patients progressive disease ( PD ) unacceptable toxicity withdrawn treatment . In Follow-Up Phase , patient whose disease progress discontinue treatment reason PD assess approximately every 6 week PD record start subsequent therapy . The study end patient assess PD , 12 month last patient enrol , whichever earlier . Patient safety monitor . Drug A , JNJ-26481585 , take orally Days 1 , 3 , 5 week dos start 6 mg escalate 12 mg. Drug B , VELCADE , give subcutaneous injection ( skin ) dose 1.3 mg/m2 Days 1 , 4 , 8 , 11 21-day cycle ( Cycles 1 8 ) Days 1 , 8 , 15 , 22 35-day cycle ( Cycles 9-11 ) . Drug C , dexamethasone , take orally day VELCADE dose 20 mg. Dosing may adjust , base tolerability .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance status score 02 Measurable secretory multiple myeloma Relapse progression myeloma follow prior systemic antineoplastic therapy Pretreatment clinical laboratory value meet protocolspecified criterion Left ventricular ejection fraction rate within normal limit Peripheral neuropathy neuralgia &gt; =2 , accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.0 Diagnosis primary amyloidosis , plasma cell leukemia , similar condition Diagnosis Waldenstrom macroglobulinemia protocolspecified immunoglobulin level Prior histonedeacetylase inhibitor therapy More 3 prior line therapy Cardiac risk factor : unstable angina myocardial infarction within precede 12 month , congestive heart failure ( New York Heart Association Class IIIV ) , know presence dilate , hypertrophic , restrictive cardiomyopathy Any cardiac abnormality , opinion investigator , medical monitor , consultant cardiologist , may place patient unacceptably increase risk study drug History following : sustain ventricular tachycardia , ventricular fibrillation , Torsades de Pointes , atrial fibrillation , cardiac arrest , Mobitz II second degree heart block , third degree heart block QTc Screening &gt; 450 m male / &gt; 470 m female Family history short QT syndrome , long QT syndrome Obligate use cardiac pacemaker Use medication may cause Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple myeloma relapse progressive follow prior therapy</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>JNJ 26481585</keyword>
	<keyword>VELCADE</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>